{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-031438","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2022-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.396553+00:00","generated_at":"2026-06-23T10:48:45.930159+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"low","headline":"Lyra presents additional Phase 2 LANTERN data for LYR-210 at ARS meeting","bullets":["Posted slide presentation with additional Phase 2 results from LANTERN trial of LYR-210 for chronic rhinosinusitis.","Data presented at 68th Annual Meeting of the American Rhinologic Society on September 10, 2022.","Top-line results from LANTERN previously reported on April 11, 2021; this update includes further analysis.","Slide deck available on Lyra's investor website and attached as exhibit to the 8-K."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-031438","json":"https://secwatch.observer/filing/0001564590-22-031438.json","markdown":"https://secwatch.observer/filing/0001564590-22-031438.md","text":"https://secwatch.observer/filing/0001564590-22-031438.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000156459022031438/0001564590-22-031438-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000156459022031438/lyra-8k_20220910.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T10:48:45.930159+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}